Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PUNUP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SHR-4597
|
|||||
| Synonyms |
SHR-4597
Click to Show/Hide
|
|||||
| Organization |
Jiangsu Hengrui Pharmaceuticals (Originator)
|
|||||
| Drug Status |
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
1.43
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-IL-4Rα antibody
|
Antibody Info | ||||
| Antigen Name |
Interleukin-4 receptor subunit alpha isoform 2 precursor
|
Antigen Info | ||||
| Payload Name |
Budesonide
|
Payload Info | ||||
| Therapeutic Target |
Glucocorticoid receptor (NR3C1)
|
Target Info | ||||
| Linker Name |
Mc-PEG3-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asthma |
1 Trials
|
1 Trials
|